Revvity, Inc. (NYSE:RVTY) Q1 2024 Earnings Call Transcript

Revvity, Inc. beats earnings expectations. Reported EPS is $0.98, expectations were $0.94. Revvity, Inc.

Related Keywords

China ,San Diego ,California ,United States ,Chinese ,America ,Joshua Waldman ,Michael Ryskin ,Vijay Kumar ,Max Krakowiak ,Josh Waldman ,Oxford Immunotec ,Steve Willoughby ,Andrew Cooper ,Raymond James ,Doug Schenkel ,Patrick Donnelly ,Jack Meehan ,Prahlad Singh ,Matt Sykes ,Matthew Sykes ,Nephron Research ,Cleveland Research ,Life Sciences Reagents ,Life Sciences ,Our Life Sciences Instrument ,Revvity Omics Lab ,Life Sciences Or Applied Genomics ,Revvity Signals Software ,Reagents Technology Licensing ,Wolfe Research ,Our Signal Software ,Fox Foundation ,Republican Congress Members ,Tour Life Sciences ,Goldman Sachs ,Specialty Pharma Services ,Revvity Inc ,Call Transcript April ,Earnings Conference ,Chief Executive Officer ,Senior Vice President ,Chief Financial ,Safe Harbor ,Newborn Screening ,Applied Genomics ,Gene Lay ,Revvity Omics ,Signals Clinical ,Signals Synergy ,Investor Day ,Investor Relations ,Life Sciences Instrument ,Signal Software ,Buying These ,Latest Insider ,Life Science ,Software Signals ,Signals Clinicals ,